Is there room for another anti-interleukin-17 treatment in the crowded psoriasis therapeutic landscape?

Br J Dermatol. 2024 May 17;190(6):e62-e63. doi: 10.1093/bjd/ljad383.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Dermatologic Agents* / therapeutic use
  • Humans
  • Interleukin-17* / antagonists & inhibitors
  • Interleukin-17* / immunology
  • Psoriasis* / drug therapy
  • Psoriasis* / immunology

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Interleukin-17